Stock HBIO HARVARD BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Harvard Bioscience, Inc.

Equities

HBIO

US4169061052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.62 USD +1.69% Intraday chart for Harvard Bioscience, Inc. -2.16% -32.34%
Apr. 09 Harvard Bioscience Reducing Headcount MT
Apr. 09 Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 116.1 167.2 287.7 115.4 228.4 157.2 - -
Enterprise Value (EV) 1 116.1 167.2 287.7 115.4 228.4 157.2 157.2 157.2
P/E ratio -25.4 x -21.5 x -705 x -12 x -66.9 x -724 x 48.3 x 21.3 x
Yield - - - - - - - -
Capitalization / Revenue 1 x 1.64 x 2.42 x 1.02 x 2.03 x 1.38 x 1.25 x 1.12 x
EV / Revenue 1 x 1.64 x 2.42 x 1.02 x 2.03 x 1.38 x 1.25 x 1.12 x
EV / EBITDA - 10.7 x 15.6 x 10.6 x 15.7 x 9.19 x 7.38 x -
EV / FCF 17 x 20.4 x 4,294 x -263 x 18.7 x 19.9 x 14.7 x 11.6 x
FCF Yield 5.88% 4.89% 0.02% -0.38% 5.36% 5.03% 6.81% 8.59%
Price to Book 1.43 x 2.23 x 3.65 x 1.64 x 3.18 x 2.06 x 1.9 x 1.67 x
Nbr of stocks (in thousands) 38,066 38,976 40,811 41,658 42,688 43,421 - -
Reference price 2 3.050 4.290 7.050 2.770 5.350 3.620 3.620 3.620
Announcement Date 2/26/20 3/10/21 3/8/22 3/9/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 116.2 102.1 118.9 113.3 112.2 114 125.6 140
EBITDA 1 - 15.67 18.5 10.84 14.55 17.1 21.3 -
EBIT 1 14.85 13.95 16.72 9.497 13.11 15.9 20.1 24.1
Operating Margin 12.78% 13.67% 14.06% 8.38% 11.68% 13.95% 16.01% 17.21%
Earnings before Tax (EBT) 1 -5.502 -7.292 -0.14 -9.179 -2.556 0.35 4.45 10.6
Net income 1 -4.687 -7.81 -0.288 -9.516 -3.415 -0.15 3.25 8
Net margin -4.03% -7.65% -0.24% -8.4% -3.04% -0.13% 2.59% 5.71%
EPS 2 -0.1200 -0.2000 -0.0100 -0.2300 -0.0800 -0.005000 0.0750 0.1700
Free Cash Flow 1 6.829 8.179 0.067 -0.438 12.24 7.9 10.7 13.5
FCF margin 5.88% 8.01% 0.06% -0.39% 10.9% 6.93% 8.52% 9.64%
FCF Conversion (EBITDA) - 52.21% 0.36% - 84.12% 46.2% 50.23% -
FCF Conversion (Net income) - - - - - - 329.23% 168.75%
Dividend per Share - - - - - - - -
Announcement Date 2/26/20 3/10/21 3/8/22 3/9/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 29.66 33.06 28.78 29.21 26.92 28.43 29.98 28.76 25.36 28.15 25.8 28.7 28.15 31.35 27.6
EBITDA 1 4.324 5.748 2.748 3.433 1.066 3.683 4.755 3.9 2.246 3.65 3 5.4 3.7 5 3.7
EBIT 1 3.948 5.278 2.366 3.057 0.702 3.369 4.434 3.572 1.841 3.265 2.6 3.8 4 5.5 -
Operating Margin 13.31% 15.97% 8.22% 10.47% 2.61% 11.85% 14.79% 12.42% 7.26% 11.6% 10.08% 13.24% 14.21% 17.54% -
Earnings before Tax (EBT) 1 0.045 1.131 -7.018 3.421 -4.69 -0.892 1.207 -2.098 -0.562 -1.103 -1.3 0.45 -0.2 1.3 -0.9
Net income 1 -0.17 0.961 -6.88 2.435 -3.405 -1.666 0.622 -0.98 -1.239 -1.818 -1.3 0.35 -0.25 1.05 -0.9
Net margin -0.57% 2.91% -23.91% 8.34% -12.65% -5.86% 2.08% -3.41% -4.89% -6.46% -5.04% 1.22% -0.89% 3.35% -3.26%
EPS 2 - 0.0200 -0.1700 0.0600 -0.0800 -0.0400 0.0100 -0.0200 -0.0300 -0.0400 -0.0250 0.005000 -0.005000 0.0250 -0.0200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/3/21 3/8/22 5/4/22 8/4/22 11/8/22 3/9/23 4/25/23 8/8/23 11/7/23 3/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 6.83 8.18 0.07 -0.44 12.2 7.9 10.7 13.5
ROE (net income / shareholders' equity) -5.72% -9.86% -0.36% -12.2% -4.7% 1.1% 5% 7.8%
ROA (Net income/ Total Assets) -2.82% -4.86% -0.18% -6.19% -2.42% 0.6% 3.1% 5%
Assets 1 166.5 160.6 159.1 153.9 141.4 -25 104.8 160
Book Value Per Share 2 2.140 1.930 1.930 1.690 1.680 1.760 1.910 2.170
Cash Flow per Share 2 0.2100 0.2400 0.1800 -0.0500 0.3300 0.1800 0.2700 0.3400
Capex 1 1.22 1.15 1.2 1.59 1.79 3.5 4 4
Capex / Sales 1.05% 1.13% 1.01% 1.4% 1.59% 3.07% 3.19% 2.86%
Announcement Date 2/26/20 3/10/21 3/8/22 3/9/23 3/7/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Harvard Bioscience, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.62 USD
Average target price
7 USD
Spread / Average Target
+93.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
HARVARD BIOSCIENCE, INC. Stock Harvard Bioscience, Inc.
-32.34% 157M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.65% 63.06B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. HBIO Stock
  4. Financials Harvard Bioscience, Inc.